Attitudes of dermatologists in the southeastern United States regarding treatment of alopecia areata: a cross-sectional survey study

Niyati Mukherjee, Dean S Morrell, Madeleine Duvic, Paul W Stewart, Lowell A Goldsmith, Niyati Mukherjee, Dean S Morrell, Madeleine Duvic, Paul W Stewart, Lowell A Goldsmith

Abstract

Background: Little evidence exists to guide treatment of alopecia areata (AA). The current practices in treatment of children compared to adults and of progressive stages of hair loss are unknown. The objective of this study was to examine the current practices of southeastern United States dermatologists for the treatment of AA.

Methods: Dermatologists were sent anonymous questionnaires regarding their treatment practices by mail. Respondents' frequencies of treatment in children compared to adults and in patchy hair loss compared to widespread hair loss were compared with Wilcoxon signed-ranks tests and Friedman tests. As a secondary source, the National Alopecia Areata Registry (NAAR) database was analyzed for patients' treatment histories.

Results: Survey results suggested that dermatologists recommend treatment less frequently for children than adults and for more advanced hair loss. NAAR data confirmed that offering no treatment for AA is relatively common.

Conclusion: Dermatologists' treatment of AA is inconsistent. A stronger evidence base will provide more consistent treatment options.

Figures

Figure 1
Figure 1
Drugs received by patients registered in the National Alopecia Areata Registry. Values shown are mention rates with approximate 95% confidence intervals. *CS = corticosteroids. ** FK506/cyclosporine/imiquimod/pimecrolimus/other. ***FK506/cyclosporine/other. ****PUVA/UVB. *****DNCB Dinitrochlorobenzene/diphencyprone/squaric acid dibutylester

References

    1. Madani S, Shapiro J. Alopecia areata update. J Am Acad Dermatol. 2000;42:549–66. doi: 10.1016/S0190-9622(00)90164-6.
    1. Freyschmidt-Paul P, Happle R, McElwee KJ, Hoffmann R. Alopecia areata: treatment of today and tomorrow. JID Symposium Proceedings. 2003;8:12–7. doi: 10.1046/j.1523-1747.2003.12165.x.
    1. Delamere FM, Sladden MM, Dobbins HM, Leonardi-Bee J. Interventions for alopecia areata. Cochrane Database of Systematic Reviews. 2008. p. CD004413.
    1. McMichael AJ, Pearce DJ, Wasserman D, Camacho FT, Fleischer AB, Feldman SR, Balkrishnan R. Alopecia in the United States: outpatient utilization and common prescribing patterns. J Am Acad Dermatol. 2007;57(2 Suppl):S49–51. doi: 10.1016/j.jaad.2006.02.045.
    1. MacDonald Hull SP, Wood ML, Hutchinson PE, Sladden M, Messenger AG. Guidelines for the management of alopecia areata. Br J Dermatol. 2003;149:692–99. doi: 10.1046/j.1365-2133.2003.05535.x.
    1. Ross EK, Shapiro J. Management of hair loss. Dermatol Clin. 2005;23:227–43.
    1. Dombrowski NC, Bergfeld WF. Alopecia areata: what to expect from current treatments. Cleveland Clin J Med. 2005;72:758–68. doi: 10.3949/ccjm.72.9.758.
    1. Lio PA. What's missing from this picture? An approach to alopecia in children. Arch Dis Child Educ Pract Ed. 2007;92:ep193–ep198.
    1. Hawit F, Silverberg NB. Alopecia areata in children. Cutis. 2008;82:104–10.
    1. Liakopoulou M, Alifieraki T, Katideniou A, Kakourou T, Tselalidou E, Tsiantis J, Stratigos J. Children with alopecia areata: psychiatric symptomatology and life events. J Am Acad Child Adolesc Psychiatry. 1997;36:678–84. doi: 10.1097/00004583-199705000-00019.
    1. Hunt N, McHale S. Reported experiences of persons with alopecia areata. J Loss Trauma. 2005;10:33–50. doi: 10.1080/15325020490890633.
    1. Mancuso G, Balducci A, Casadio C, Farina P, Staffa M, Valenti L, Milani M. Efficacy of betamethasone valerate foam formulation in comparison with betamethasone dipropionate lotion in the treatment of mild-to-moderate alopecia areata: A multicenter, prospective, randomized, controlled, investigator-blinded trial. Int J Dermatol. 2003;42:572–5. doi: 10.1046/j.1365-4362.2003.01862.x.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner